FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159651421> ?p ?o ?g. }

• W3159651421 endingPage "1690" @default.
• W3159651421 startingPage "1677" @default.
• W3159651421 abstract "Adeno-associated virus (AAV)-mediated gene therapy is a novel treatment promising to reduce morbidity associated with hemophilia. Although multiple clinical trials continue to evaluate efficacy and safety, limited cost-effectiveness data have been published. This study compared the potential cost-effectiveness of AAV-mediated factor IX (FIX)-Padua gene therapy for patients with severe hemophilia B in the United States vs on-demand FIX replacement and primary FIX prophylaxis, using either standard or extended half-life FIX products. A microsimulation Markov model was constructed, and transition probabilities between health states and utilities were informed by using published data. Costs were aggregated by using a microcosting approach. A time horizon from 18 years old until death, from the perspective of a third-party payer in the United States, was conducted. Gene therapy was more cost-effective than both alternatives considering a $150 000/quality-adjusted life-year threshold. The price for gene therapy was assumed to be $2 000 000 in the base case scenario; however, one of the 1-way sensitivity analyses was conducted by using observed manufacturing, administration, and 5-year follow-up costs of $87 198 for AAV-mediated gene therapy vector as derived from the manufacturing facility and clinical practice at St Jude Children's Research Hospital. One-way sensitivity analyses revealed 10 of 102 scenarios in which gene therapy was not cost-effective compared with alternative treatments. Notably, gene therapy remained cost-effective in a hypothetical scenario in which we estimated that the discounted factor concentrate price was 20% of the wholesale acquisition cost in the United States. Probabilistic sensitivity analysis estimated gene therapy to be cost-effective at 92% of simulations considering a $150 000/quality-adjusted life-year threshold. In conclusion, based on detailed simulation inputs and assumptions, gene therapy was more cost-effective than on-demand treatment and prophylaxis for patients with severe hemophilia B." @default.
• W3159651421 created "2021-05-10" @default.
• W3159651421 creator A5009112260 @default.
• W3159651421 creator A5015947780 @default.
• W3159651421 creator A5032635874 @default.
• W3159651421 creator A5035133092 @default.
• W3159651421 creator A5039185570 @default.
• W3159651421 creator A5053244337 @default.
• W3159651421 creator A5056195915 @default.
• W3159651421 creator A5063456712 @default.
• W3159651421 creator A5073816998 @default.
• W3159651421 creator A5075104279 @default.
• W3159651421 creator A5083376438 @default.
• W3159651421 creator A5085010022 @default.
• W3159651421 creator A5086688631 @default.
• W3159651421 date "2021-11-04" @default.
• W3159651421 modified "2023-10-16" @default.
• W3159651421 title "The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective" @default.
• W3159651421 cites W1969271703 @default.
• W3159651421 cites W1969941406 @default.
• W3159651421 cites W1973059778 @default.
• W3159651421 cites W1976624075 @default.
• W3159651421 cites W2038056060 @default.
• W3159651421 cites W2039878142 @default.
• W3159651421 cites W2045991410 @default.
• W3159651421 cites W2050334237 @default.
• W3159651421 cites W2074411955 @default.
• W3159651421 cites W2076003266 @default.
• W3159651421 cites W2098538423 @default.
• W3159651421 cites W2100770509 @default.
• W3159651421 cites W2109131496 @default.
• W3159651421 cites W2116131438 @default.
• W3159651421 cites W2122317738 @default.
• W3159651421 cites W2127285750 @default.
• W3159651421 cites W2147873611 @default.
• W3159651421 cites W2258158018 @default.
• W3159651421 cites W2315516779 @default.
• W3159651421 cites W2519603001 @default.
• W3159651421 cites W2626358278 @default.
• W3159651421 cites W2749027583 @default.
• W3159651421 cites W2773253161 @default.
• W3159651421 cites W2773565340 @default.
• W3159651421 cites W2795262817 @default.
• W3159651421 cites W2808973643 @default.
• W3159651421 cites W2883732986 @default.
• W3159651421 cites W2888504165 @default.
• W3159651421 cites W2889738396 @default.
• W3159651421 cites W2901088499 @default.
• W3159651421 cites W2914965689 @default.
• W3159651421 cites W2944757191 @default.
• W3159651421 cites W2952841232 @default.
• W3159651421 cites W2964088387 @default.
• W3159651421 cites W2972722566 @default.
• W3159651421 cites W2982694372 @default.
• W3159651421 cites W2999519991 @default.
• W3159651421 cites W3003053451 @default.
• W3159651421 cites W3017556747 @default.
• W3159651421 cites W3030023178 @default.
• W3159651421 cites W3047046471 @default.
• W3159651421 cites W3104935789 @default.
• W3159651421 cites W71674269 @default.
• W3159651421 doi "https://doi.org/10.1182/blood.2021010864" @default.
• W3159651421 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33895800" @default.
• W3159651421 hasPublicationYear "2021" @default.
• W3159651421 type Work @default.
• W3159651421 sameAs 3159651421 @default.
• W3159651421 citedByCount "17" @default.
• W3159651421 countsByYear W31596514212021 @default.
• W3159651421 countsByYear W31596514212022 @default.
• W3159651421 countsByYear W31596514212023 @default.
• W3159651421 crossrefType "journal-article" @default.
• W3159651421 hasAuthorship W3159651421A5009112260 @default.
• W3159651421 hasAuthorship W3159651421A5015947780 @default.
• W3159651421 hasAuthorship W3159651421A5032635874 @default.
• W3159651421 hasAuthorship W3159651421A5035133092 @default.
• W3159651421 hasAuthorship W3159651421A5039185570 @default.
• W3159651421 hasAuthorship W3159651421A5053244337 @default.
• W3159651421 hasAuthorship W3159651421A5056195915 @default.
• W3159651421 hasAuthorship W3159651421A5063456712 @default.
• W3159651421 hasAuthorship W3159651421A5073816998 @default.
• W3159651421 hasAuthorship W3159651421A5075104279 @default.
• W3159651421 hasAuthorship W3159651421A5083376438 @default.
• W3159651421 hasAuthorship W3159651421A5085010022 @default.
• W3159651421 hasAuthorship W3159651421A5086688631 @default.
• W3159651421 hasBestOaLocation W31596514211 @default.
• W3159651421 hasConcept C104317684 @default.
• W3159651421 hasConcept C111599444 @default.
• W3159651421 hasConcept C112930515 @default.
• W3159651421 hasConcept C126322002 @default.
• W3159651421 hasConcept C127413603 @default.
• W3159651421 hasConcept C177713679 @default.
• W3159651421 hasConcept C22212356 @default.
• W3159651421 hasConcept C2780015235 @default.
• W3159651421 hasConcept C2781221834 @default.
• W3159651421 hasConcept C3019080777 @default.
• W3159651421 hasConcept C535046627 @default.
• W3159651421 hasConcept C54355233 @default.
• W3159651421 hasConcept C64332521 @default.

• next